Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dermatophagoides pteronyssinus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Dermatophagoides pteronyssinus. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-000870-79 Sponsor Protocol Number: 101-PG-PSC-186 Start Date*: 2012-02-17
    Sponsor Name:Laboratorios LETI, S.L.U.
    Full Title: Prospective study to evaluate the safety of a 4-month treatment with Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml) in pa...
    Medical condition: Allergic rhinitis or rhinoconjunctivitis with or without mild persistent or intermittent asthma, to Dermatophagoides pteronyssinus or Dermatophagoides pteronyssinus and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005394-45 Sponsor Protocol Number: MM09-STD-011 Start Date*: 2015-09-03
    Sponsor Name:Inmunotek, S.L.
    Full Title: Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extract. Determination of the allergenic potency in vivo histamine equivalent units (HEP)
    Medical condition: Allergy to mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004429-42 Sponsor Protocol Number: DIA-Der-02-14 Start Date*: 2015-02-19
    Sponsor Name:Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas, S.A.
    Full Title: Open multicenter clinical trial to confirm the maximum no reactive dose of allergoid of polymerized Dermatophagoides pteronyssinus, in patients with allergic rhinoconjunctivitis or mild or moderate...
    Medical condition: Allergic patients to Dermatophagoides pteronyssinus, with rhinoconjunctivitis or mild or moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021428 - Immune system disorders 10057631 House dust allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-003680-39 Sponsor Protocol Number: ECRL1 Start Date*: 2009-08-25
    Sponsor Name:Servicio de Alergia. Hospital Civil. Málaga (Spain)
    Full Title: Valoración de la eficacia de un extracto de Dermatophagoides pteronyssinus, valorado en unidades de masa y administrado por vía subcutánea, en el tratamiento de la rinitis alérgica local. Estudio r...
    Medical condition: Pacientes con rinitis alergica perenne con solo evidencia nasal de mecanismos inmunológicos específicos, y con test cutaneos e IgE específica en suero negativos. Se valorará la eficacia de la inmun...
    Disease: Version SOC Term Classification Code Term Level
    9 10001725 Allergic rhinitis due to other allergen LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001939-31 Sponsor Protocol Number: 101-PR-PRI-196 Start Date*: 2013-02-13
    Sponsor Name:LABORATORIOS LETI S.L.U
    Full Title: Biological standardization of Dermatophagoides pteronyssinus allergen extract to determine the biological activity in histamine equivalent units (HEP).
    Medical condition: Allergy to Dermatophagoides pteronyssinus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002177-62 Sponsor Protocol Number: SU-M-01 Start Date*: 2012-11-05
    Sponsor Name:ALK-Abelló A/S
    Full Title: A Dose Response Evaluation of SLIToneULTRA HDM Mix Immunotherapy
    Medical condition: Allergic rhinitis induced by house dust mites (HDM)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005636-28 Sponsor Protocol Number: E04/05/PP-M Start Date*: 2006-08-29
    Sponsor Name:ALK-ABELLÓ, S.A.
    Full Title: Valoración de la eficacia a corto plazo de un extracto de Dermatophagoides pteronyssinus, valorado en unidades de masa y administrado por vía subcutánea, en el tratamiento del asma alérgico. Estudi...
    Medical condition: Asma alérgico perenne, con/sin síntomas de rinitis o rinoconjuntivitis, por sensibilización a Dermatophagoides pteronyssinus.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003930-41 Sponsor Protocol Number: DME_01 Start Date*: 2007-11-20
    Sponsor Name:Curalogic A/S
    Full Title: Assessment of the Maximal Tolerated Dose of a Microencapsulated House Dust Mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) Extract (MHDME) in Subjects with House Dust Mite Allerg...
    Medical condition: Allergic rhinoconjunctivitis due to house mite dust allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002321-22 Sponsor Protocol Number: SL-71A Start Date*: 2020-08-06
    Sponsor Name:Roxall Medicina España S.A.
    Full Title: PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM HOUSE DUST MITE ALLERGY
    Medical condition: Patients with house dust mites related allergic rhinitis/rhino-conjunctivitis (with or without well controlled asthma).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000172-26 Sponsor Protocol Number: 1301-PG-PSC-203 Start Date*: 2014-06-26
    Sponsor Name:Laboratorios LETI S.L.U
    Full Title: A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatoph...
    Medical condition: Allergic rhinitis or rihinoconjuntivitis, with controlled allergic asthma due to D. pteronyssinus and Blomia tropicalis or Lepidoglyphus destructor sensitization.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001965-16 Sponsor Protocol Number: 101-AC-OSL-124 Start Date*: 2005-01-26
    Sponsor Name:LABORATORIOS LETI
    Full Title: ENSAYO CLÍNICO, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO CONTROLADO CON PLACEBO, DE INMUNOTERAPIA SUBLINGUAL CON EXTRACTO ALERGÉNICO DE DERMATOPHAGOIDES PTERONYSSINUS EN PACIENTES CON ASMA, DE INTE...
    Medical condition: La inmunoterapia consiste en la administración, generalmente subcutánea, de dosis progresivamente crecientes del material alergénico al que el paciente está sensibilizado, con el fin de mejorar la ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004583-30 Sponsor Protocol Number: BIA-DPT-P2-001 Start Date*: 2012-01-16
    Sponsor Name:BIAL Industrial Farmaceutica
    Full Title: A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCT...
    Medical condition: Allergic rhinoconjunctivitis with or without associated asthma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004262-34 Sponsor Protocol Number: MM09-SIT-023 Start Date*: 2020-04-28
    Sponsor Name:Inmunotek, S.L.
    Full Title: Randomized, placebo-controlled, prospective clinical trial of efficacy and safety for the treatment of rhinitis/rhinoconjunctivitis and asthma against a mixture of Dermatophagoides pteronyssinus an...
    Medical condition: House dust mites allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004223-46 Sponsor Protocol Number: SL75.14 Start Date*: 2015-09-16
    Sponsor Name:Stallergenes
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with ...
    Medical condition: House dust mite allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10001725 Allergic rhinitis due to other allergen LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) SK (Completed) DE (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000602-23 Sponsor Protocol Number: 101-PG-COM-144 Start Date*: 2007-09-17
    Sponsor Name:Laboratorios LETI S.L.
    Full Title: A randomized double blind, placebo controlled study to evaluate the efficacy and security of immunotherapy with a depigmented and polymerized allergen extract of Dermatophagoides pteronyssinus in p...
    Medical condition: Mild to moderate asthma caused by sensitization againts dust mite Dermatophagoides Pteronyssinus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PT (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2011-002317-10 Sponsor Protocol Number: SC-31A Start Date*: 2019-04-17
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001316-31 Sponsor Protocol Number: E01/04/SLIT1-M Start Date*: Information not available in EudraCT
    Sponsor Name:ALK-ABELLO, S.A.
    Full Title: TOLERABILIDAD DE LAS VACUNAS ALERGÉNICAS VALORADAS EN UNIDADES DE MASA Y ADMINISTRADAS POR VÍA SUBLINGUAL. ESTUDIO RANDOMIZADO DOBLE CIEGO CONTROLADO CON PLACEBO EN PACIENTES CON ENFERMEDAD ALÉRGIC...
    Medical condition: Rinitis o rinoconjuntivitis alérgica perenne (ácaros) o estacional (gramíneas) con/sin síntomas de asma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000446-34 Sponsor Protocol Number: MT-18 Start Date*: 2020-07-14
    Sponsor Name:ALK-Abelló A/S
    Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-000487-28 Sponsor Protocol Number: VO72.12 Start Date*: 2013-08-20
    Sponsor Name:STALLERGENES SA
    Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
    Medical condition: house dust mite-associated allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005362-35 Sponsor Protocol Number: VB-01-DPHLOLEG Start Date*: 2013-04-09
    Sponsor Name:Instituto de Inmunología y Alergia INMUNAL SAU
    Full Title: Biological standardization of pollen of Phleum pratense, Olea europaea, mite extract Dermatophagoides pteronyssinus and animal allergen Felis domesticus. Open label, single center, phase II study.
    Medical condition: Biological standardization for allergenic extracts in patients with hipersensibility to extracts
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:07:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA